{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:27:10Z","timestamp":1793950030182,"version":"4.8.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T00:00:00Z","timestamp":1225324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p>\n                    <jats:bold>Summary.\u2002<\/jats:bold>\n                    Plasminogen activator inhibitor type 1 (PAI\u20101) is an important component of the coagulation system that down\u2010regulates fibrinolysis in the circulation. Reduced PAI\u20101 levels may result in increased fibrinolysis and an associated bleeding diathesis. Clear documentation of PAI\u20101 deficiency as a cause of a bleeding disorder has been rare. PAI\u20101 was initially identified in the 1980s, and the first reported case of PAI\u20101 deficiency appeared in 1989. Several reports followed, although only two identified an underlying genetic defect. These reports of PAI\u20101 deficiency suggest that affected individuals exhibit mild to moderate bleeding symptoms, including epistaxis, menorrhagia, and delayed bleeding after trauma or surgical procedures. Affected individuals rarely exhibit spontaneous bleeding events commonly seen in other procoagulant deficiencies. The majority of bleeding events are controlled with antifibrinolytic agents, such as tranexamic acid and \u03b5\u2010aminocaproic acid. A major issue that contributes to difficulty in establishing an accurate diagnosis of PAI\u20101 deficiency is that the activity assay is accurate in detection of elevated levels but not at the lowest range. Reported normal ranges begin at zero, thereby making a deficiency state because of a dysproteinaemia difficult to distinguish from that of a normal unaffected individual. Although the antigen assay may be helpful in some circumstances, it assists only with complete quantitative disorders. Because of lack of standardized commercially available PAI\u20101 activity assay sensitive in the lowest range, the true prevalence of this rare condition has not been established.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01834.x","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T09:40:03Z","timestamp":1283420403000},"page":"1255-1260","source":"Crossref","is-referenced-by-count":135,"title":["Plasminogen activator inhibitor type 1 deficiency"],"prefix":"10.1111","volume":"14","author":[{"given":"R.","family":"MEHTA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"SHAPIRO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-01-0033"},{"key":"e_1_2_12_3_2","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1016\/S0021-9258(17)42691-3","article-title":"Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells","volume":"259","author":"Van Mourik JA","year":"1984","journal-title":"J Biol Chem"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.18.6776"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422406"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114076"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.3.528.528"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212103272406"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01709.x"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-005-0048-x"},{"key":"e_1_2_12_11_2","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V81.9.2357.2357","article-title":"Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding","volume":"81","author":"Lee MH","year":"1993","journal-title":"Blood"},{"key":"e_1_2_12_12_2","first-page":"286","article-title":"Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor\u20101 deficiency","volume":"29","author":"Minowa H","year":"1999","journal-title":"Haemostasis"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00914.x"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602960401000316"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02585.x"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0925-5710(96)00460-4"},{"key":"e_1_2_12_17_2","first-page":"133","article-title":"Oral management of a patient with a plasminogen activator inhibitor (PAI\u20101) deficiency: case report","volume":"16","author":"Tanimura LK","year":"1994","journal-title":"Pediatr Dent"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200501000-00013"},{"key":"e_1_2_12_19_2","first-page":"335","volume-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","author":"Booth NA","year":"2006"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(01)00293-6"},{"key":"e_1_2_12_21_2","first-page":"365","volume-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","author":"Yepes M","year":"2006"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.1.101"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3282dded21"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.204"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200312000-00008"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.06.014"},{"key":"e_1_2_12_27_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1160\/TH03-12-0784","article-title":"Plasminogen activator inhibitor\u2010I and tumour growth, invasion, and metastasis","volume":"91","author":"Durand MK","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-216"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0898-923"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01834.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01834.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:30:16Z","timestamp":1697167816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01834.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,30]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01834.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01834.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,30]]}}}